Stocks to Buy for the Next Decade: ResMed (RMD)
Who knew that sleep apnea paid so well?
ResMed Inc. (NYSE:RMD) manufactures medical devices and provides cloud-based software applications for medical professionals to treat and manage sleep apnea and chronic obstructive pulmonary disease (COPD). Treating 2 million patients daily, ResMed has become good at reducing healthcare costs by minimizing the effects of chronic disease.
Good businesses make and save people and companies money. ResMed does both.
Over the past decade through April 17, ResMed has delivered an annual return to shareholders of 11.9%, 478 basis points greater than the S&P 500. Year-to-date, RMD is up 12.1% and on its way to its fourth year of gains in the past five.
According to a recent study, 26% of adults have sleep apnea — a disorder that can wreak havoc on a person’s heart, not to mention a marriage due to both partners’ lack of sleep. My dad died as a result of COPD, a disease that effects more than 200 million people worldwide and costs the healthcare system more than $50 billion per year in the U.S. alone.
ResMed has growth opportunities in Latin America, Eastern Europe and China and India — all huge markets that will keep it busy for the next decade and beyond.
Of all the stocks to buy for the next decade, ResMed is my pick for most reliable given the markets it serves.
As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities.